NCT06279130 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06279130
Title	Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)
Acronym	NEOASIS
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	The Netherlands Cancer Institute
Indications	Advanced Solid Tumor prostate cancer cervical cancer small intestine adenocarcinoma small intestine cancer anal canal cancer gastric adenocarcinoma endometrial cancer esophagus squamous cell carcinoma esophagus adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma urinary bladder cancer breast cancer rectum adenocarcinoma sarcoma ovarian cancer triple-receptor negative breast cancer
Therapies	Botensilimab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Balstilimab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Balstilimab + Botensilimab
Age Groups:	adult \| senior
Covered Countries	NLD

Facility	Status	City	State	Zip	Country	Details
The Netherlands Cancer Institute	RECRUITING	Amsterdam	North Holland	1066 CX	Netherlands	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06279130Clinical Trial Detail